Released Nov 5, 2026, after the close
10-Q filed Nov 5, 2026, 36 days after period end · 0001193125-26-450194
What the release said
On November 5, 2026, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026.
Revelation Biosciences issued a press release on November 5, 2026 announcing its financial results for the three and nine months ended September 30, 2026.¶1
Net loss for the three months ended September 30, 2026 was $3.3 million, or $5.92 per share, compared to $1.9 million, or $49.51 per share, a year earlier.¶2
Net loss for the nine months ended September 30, 2026 was $9.6 million, or $29.37 per share, compared to $6.4 million, or $273.33 per share, for the same period in 2025.¶2
Cash and cash equivalents were $9.1 million as of September 30, 2026, compared to $10.7 million as of December 31, 2025, and are stated to fund operations into the second quarter of 2027.¶3
Revelation released an independent market assessment showing a potential $94 billion total addressable market for Gemini and selected a full-service CRO for the upcoming acute kidney injury study.¶4¶5
- Net loss, three months ended September 30, 2026
- $3.3 million Compared with $1.9 million for the three months ended September 30, 2025¶2
- Net loss per share, basic and diluted, three months ended September 30, 2026
- $5.92 Compared with $49.51 for the three months ended September 30, 2025¶2
- Net loss, nine months ended September 30, 2026
- $9.6 million Compared with $6.4 million for the nine months ended September 30, 2025¶2
- Net loss per share, basic and diluted, nine months ended September 30, 2026
- $29.37 Compared with $273.33 for the nine months ended September 30, 2025¶2
- Cash and cash equivalents
- $9.1 million As of September 30, 2026, compared with $10.7 million as of December 31, 2025¶3
- Potential total addressable market for Gemini
- $94 billion Stated in an independent market assessment released by the company¶4
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$3.32M | -$1.91M | -$2.24M | -$2.63M |
| EPS Diluted | -$5.92 | -$49.51 | -$40.15 | -$9.94 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR